Short Interest in Briacell Therap (NASDAQ:BCTX) Grows By 174.9%

Briacell Therap (NASDAQ:BCTX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 281,381 shares, a growth of 174.9% from the December 15th total of 102,341 shares. Currently, 15.8% of the company’s stock are short sold. Based on an average daily trading volume, of 74,326 shares, the short-interest ratio is currently 3.8 days. Based on an average daily trading volume, of 74,326 shares, the short-interest ratio is currently 3.8 days. Currently, 15.8% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $320.00.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC purchased a new stake in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors.

Briacell Therap Stock Performance

Shares of BCTX opened at $4.49 on Friday. The stock has a market capitalization of $8.44 million, a P/E ratio of -0.10 and a beta of 1.38. Briacell Therap has a 1 year low of $4.46 and a 1 year high of $98.20. The company’s fifty day moving average is $8.93 and its two-hundred day moving average is $10.52.

Briacell Therap (NASDAQ:BCTX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($4.35) EPS for the quarter, beating analysts’ consensus estimates of ($12.11) by $7.76. Sell-side analysts predict that Briacell Therap will post -2.45 EPS for the current year.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.